Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Our work is reader-supported. Sign up to our free or paid plans here.
This morning, Compass Pathways shared the first cut of Phase 3 data for a classical psychedelic, reporting a statistically significant MADRS difference vs. placebo and a reassuring safety profile in its trial of COMP360 psilocybin for treatment-resistant depression. Here, we provide our quick-take analysis and speak with company execs about the news.
Australia’s largest private health insurer, Medibank, has launched a first-of-its-kind funding program for MDMA-assisted therapy for PTSD as part of its ‘innovative psychotherapy program’. That makes it the first payor in the country to back psychedelic-assisted psychotherapy.
EU Member States as Laboratories of Democracy? Conference Discusses Czechia’s Psychedelic Future at Prague Castle • At ‘the Davos of Mental Health’, Investors Eye Psychedelics’ Next Chapter • Psychedelic Alpha at Psychedelic Science 2025 • High-Dose LSD Shows Potential in Depression Trial, But Findings Are Fragile • and more…
Explore or interactive database of psychedelic patent activity in May 2025 via our Pα+ interface. We also cover a handful of related headlines: from Gilgamesh Pharmaceuticals’ IP around its lead candidate, GM-2505, through to new published applications from Reconnect Labs that claim compositions of 5-MeO-DMT.
The Class of Bulletin #100: Where Are They Now? • Can Czechia Deliver on Psilocybin Access and Provide a Model for the Continent? • A Closer Look at atai’s Potential Acquisition of Beckley Psytech • Q1’25 Psychedelic Lobbying Update • Holy Trips and Hot Takes: Religious Leaders Study Finally Published • and much, much more…
Psychedelic drug developers atai Life Sciences and Beckley Psytech are set to merge in a transaction that would value Beckley at around $370M. The combined entity, which would be named atai Beckley, would have a leadership team and Board reflective of both companies. Psychedelic Alpha spoke with sources close to the companies to learn more about the proposed merger and financing.
Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.
The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.
It’s exclusively available to our Pα+ subscribers, with new content added regularly.
Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.
Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.
Archived versions of our Psychedelic News Feed.
This is an archived version of our Psychedelic News Feed, from September 2 to December 29, 2024.
This is an archived version of our Psychedelic News Feed, from March 4, 2024 – September 1, 2024.
A special version of our Psychedelic News Feed to mark April 1st, 2024.
This is an archived version of our Psychedelic News Feed, from February 5 2024 – March 3 2024.
This is an archived version of our Psychedelic News Feed, from January 8 2024 – February 4 2024.
This is an archived version of our Psychedelic News Feed, from December 11 2023 – January 7 2024.
Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond
Insights and interviews delivered to your inbox. No spam, just valuable information.
